Pediatric migraine: Neurodevelopmental mechanisms, clinical phenotypes, and modern therapeutics

Table 1 Mechanistic comparison between pediatric and adult-onset migraine

Feature	Pediatric onset	Adult onset
Primary driver	Genetic load/channelopathy	Environment/hormonal/allostatic load
Glutamate profile	Often decreased in the visual cortex	Typically increased
Dominant neuropeptides	PACAP, VIP, and CGRP	Primarily CGRP
Pain pattern	Bilateral (immature modulation)	Unilateral (mature lateralization)
Autonomic involvement	High (GI and facial symptoms)	Moderate (standard cranial symptoms)

PACAP: Pituitary adenylate cyclase-activating polypeptide; VIP: Vasoactive intestinal polypeptide; CGRP: Calcitonin gene-related peptide; GI: Gastrointestinal.

Table 2 Key clinical features differentiating pediatric headache types

Feature	Migraine	Tension-type headache	Secondary headache
Typical onset	Episodic, recurrent	Gradual, often stress-related	Acute or progressive
Pain quality	Pulsating/throbbing	Pressing/tight	Variable
Pain location	Bilateral (frontotemporal) in children	Bilateral, diffuse	Often focal or occipital
Intensity	Moderate to severe	Mild to moderate	Variable, often severe
Activity worsens pain	Yes	No	Variable
Nausea/vomiting	Common	Absent	Possible
Photo-/phonophobia	Common	Absent or mild	Variable
Autonomic features	Common in children	Rare	Possible
Neurological exam	Normal	Normal	Often abnormal
Response to sleep	Marked improvement	Minimal effect	Poor or absent

Table 3 Standardized acute pharmacotherapy: Weight-based dosing

Agent	Pediatric dose (mg/kg)	Max single dose	Monthly limit	Monitoring/safety
Ibuprofen	10 mg/kg	800 mg	< 14 days/month	Take with food; avoid in active gastritis or renal impairment
Acetaminophen	15 mg/kg	1000 mg	< 14 days/month	Hepatic safety; check for “hidden” sources in OTC products
Naproxen	5-10 mg/kg	500 mg	< 14 days/month	Preferred for long-duration attacks due to 12 hours half-life
Sumatriptan	Nasal spray: 5-20 mg	20 mg	< 9 days/month	Monitor for “triptan sensations” (chest/neck tightness)

OTC: Over-the-counter.

Table 4 The different Food and Drug Administration-approved triptans used to treat childhood migraine

Medication	Age group (FDA)	Age group (EMA)	Key features
Rizatriptan (Maxalt)	6-17 years	≥ 18 years1	Currently the only triptan FDA-approved for children as young as 6. Available as an ODT
Zolmitriptan nasal spray	12-17 years	12-17 years	First nasal-delivered triptan approved for adolescents. Offers rapid absorption and high efficacy for associated symptoms
Almotriptan	12-17 years	12-17 years	Often cited for having a superior tolerability profile with fewer “triptan sensations” (chest/neck tightness)
Sumatriptan/naproxen	12-17 years		A fixed-dose combination (Treximet) that targets both the neural (triptan) and inflammatory (NSAID) pathways

¹While European regulators (European Medicines Agency) often defer to national approvals for younger ages, sumatriptan nasal spray is the most widely approved pediatric triptan across Europe for those > 12 years.

EMA: European Medicines Agency; FDA: Food and Drug Administration; ODT: Orally disintegrating tablet; NSAID: Non-steroidal anti-inflammatory drugs.

Table 5 Comparative overview of traditional vs emerging acute therapies

Feature	Triptans	Gepants (emerging)	Ditans (emerging)
Primary target	5-HT1B/1D	CGRP receptor	5-HT1F receptor
Vasoconstriction	Yes	No	No
Primary SE	Chest/neck tightness	Nausea, dry mouth	Dizziness, somnolence
Pediatric status	FDA/EMA approved (selected)	Phase 3 trials (6-17 years)	Ongoing trials (6-17 years)
Clinical role	Standard 2nd-line	Refractory/vascular contraindication	Refractory/vascular contraindication

SE: Side effects; EMA: European Medicines Agency; FDA: Food and Drug Administration; CGRP: Calcitonin gene-related peptide.

Table 6 Traditional pharmacologic preventives for pediatric migraine: Rapid comparison

Agent	Topiramate	Amitriptyline	Propranolol
Mechanism of action	Enhances GABAergic inhibition; inhibits glutamatergic transmission; ion channel modulation	Serotonergic and noradrenergic reuptake inhibition	Non-selective β-adrenergic blockade
Strength of evidence (pediatrics)	Moderate (FDA-approved ≥ 12 years; CHAMP showed no superiority to placebo)	Moderate (FDA-approved ≥ 12 years; CHAMP showed no superiority to placebo)	Low-moderate (small trials, mixed results)
Typical starting pediatric dose1	Start 0.5-1 mg/kg/day	Start 0.25-0.5 mg/kg at bedtime	0.5 mg/kg (divided)
Titration (weekly)	Increase by 0.5 mg/kg to 1-2 mg/kg/day	Increase by 0.25 mg/kg	Increase by 0.5 mg/kg
Max dose	Max 100 mg/day	Max 1 mg/kg/day (usually ≤ 50 mg)	2-4 mg/kg (max 160 mg)
Key limitations/monitoring	Cognitive slowing, paresthesia, weight loss	Sedation, weight gain, anticholinergic effects	Contraindicated in children with asthma or diabetes
Practical considerations	Avoid children with learning difficulties; monitor weight, cognition, and mood	Baseline ECG recommended; high placebo response	May benefit comorbid anxiety; monitor heart rate blood pressure and exercise tolerance
Contraindication	Nephrolithiasis, glaucoma	Cardiac conduction defects	Asthma, diabetes, depression

¹Doses reflect commonly used ranges from pediatric headache guidelines and expert consensus; individualization and slow titration are recommended.

GABA: Gamma-aminobutyric acid; FDA: Food and Drug Administration; ECG: Electrocardiogram.

Table 7 Comparison of common pediatric migraine nutraceuticals

Nutraceutical	Biological rationale	Clinical evidence	Typical pediatric dosing	Key adverse effects
Magnesium	Modulates NMDA receptors; inhibits cortical spreading depression; reduces CGRP release	Modest but supportive; specifically effective for migraines with aura	5-10 mg/kg/day (elemental), often divided	Dose-dependent diarrhea; abdominal cramping
Riboflavin (vitamin B2)	Addresses mitochondrial dysfunction by enhancing electron transport chain efficiency	Some randomized trials show reduced frequency; high placebo response noted in children	200-400 mg/day (often used in doses higher than RDA)	Benign bright yellow discoloration of urine (chromaturia)
Coenzyme Q10	Acts as an antioxidant and essential cofactor in mitochondrial energy production	Shown to reduce headache frequency and severity in children with low levels	1-3 mg/kg/day (typically 100 mg daily)	Rare gastrointestinal upset or insomnia; generally extremely well-tolerated

NMDA: N-methyl-D-aspartate; CGRP: Calcitonin gene-related peptide; RDA: Recommended dietary allowance.

Table 8 Comparison of calcitonin gene-related peptide monoclonal antibodies in pediatric patients

Feature	Erenumab (Aimovig)	Fremanezumab (Ajovy)	Galcanezumab (Emgality)	Eptinezumab (Vyepti)
Mechanism	Targets the CGRP receptor	Targets the CGRP ligand	Targets the CGRP ligand	Targets the CGRP ligand
Route	Subcutaneous injection	Subcutaneous injection	Subcutaneous injection	Intravenous infusion
Dosing frequency	Monthly	Monthly or quarterly	Monthly	Quarterly (every 12 weeks)
Pediatric evidence	Phase 3 trials (OASIS) recently completed/ongoing.	Strong evidence from phase 3 SPACE study; FDA filed for pediatric indication	Phase 3 trials ongoing; shown efficacy in small retrospective cohorts	Phase 3 trials (PROSPECT-1) ongoing; unique for its IV rapid onset
Key safety notes	Association with constipation (unique to receptor blockade)	Most common AE is injection-site erythema	Most common AE is injection-site reaction	Potential for infusion-related reactions; high safety rating in meta-analyses

CGRP: Calcitonin gene-related peptide; FDA: Food and Drug Administration; AEs: Adverse events.

Table 9 Comparison of key pediatric neuromodulation devices used for migraine management

Device/modality	Target/mechanism	Pediatric age approval	Acute use	Preventive use	Evidence and notes
Remote electrical neuromodulation (Nerivio®)	Upper-arm electrical stimulation enhancing conditioned pain modulation. This descending analgesic mechanism reduces pain in distant body regions (the head). It stimulates C and Aδ nerve fibers	FDA-cleared ≥ 12 years; expanding to 8 years in some jurisdictions	Yes	Yes	Open-label and real-world data show pain relief and functional improvement in adolescents; minimal AEs and high acceptability
External trigeminal nerve stimulation (Cefaly®)	Supraorbital trigeminal nerve stimulation. The device stimulates the supraorbital trigeminal nerve, the primary pathway for migraine pain, helping to modulate and desensitize it	Used off-label in pediatrics; FDA cleared for adults	Yes	Yes	Adult data supports efficacy/safety; device modulates trigeminal afferents with minimal side effects, and pediatric tolerability appears acceptable
Single-pulse transcranial magnetic stimulation (eNeura/SAVI Dual™)	Magnetic pulses modulating cortical excitability by creating a small electrical current in the cortex to “reset” overactive brain nerves associated with migraines, without causing pain	FDA-cleared ≥ 12 years (adolescents)	Yes	Yes	Open-label adolescent studies show feasibility and tolerability; larger RCTs needed for efficacy confirmation
Non-invasive vagus nerve stimulation (gammaCore®)	Cervical vagal nerve stimulation influencing brainstem pain pathways	FDA-cleared ≥ 12 years	Yes	Yes	Small pediatric studies suggest relief in adolescents; generally, well tolerated with mild neck discomfort
External combined occipital and trigeminal neurostimulation (Relivion®)	Dual occipital + trigeminal stimulation	Adult cleared; pediatric off label	Yes	Potential	Adult data supports acute migraine use, pediatric evidence currently limited

AEs: Adverse events; FDA: Food and Drug Administration; RCTs: Randomized controlled trials.